Clinical outcome and olanzapine plasma levels in acute schizophrenia
- 1 January 2005
- journal article
- clinical trial
- Published by Cambridge University Press (CUP) in European Psychiatry
- Vol. 20 (1), 55-60
- https://doi.org/10.1016/j.eurpsy.2004.09.009
Abstract
PurposeThis open label study was performed to evaluate the relationship between the plasma concentration of olanzapine and the response in acute schizophrenic inpatients.Material and methodsA total of 54 inpatients, 38 males and 16 females, age ranging from 18 to 75 years, affected by Schizophrenia (DSM IV criteria) during an exacerbation phase were included in the study. Olanzapine (OLZ) was started at a dose of 5–20 mg/day and was increased to a mean dose of 15.27 mg ±5.53 S.D. Patients were evaluated at baseline, and after 2 weeks, by using BPRS, PANNS, HRS-D, EPSE, and ACS.ResultsBPRS and total PANSS showed a statistically significant improvement at the end of the study. Olanzapine plasma levels (PL) ranged from 5 to 120 ng/ml (mean 33.15 ng/ml ± 28.28 S.D.) and showed a positive correlation with OLZ dosage. A significant curvilinear correlation between OLZ PL and clinical improvement (BPRS, PANSS and HRS-D percent of amelioration) was observed.ConclusionOlanzapine plasma level determination seems to be a useful tool in optimizing acute treatment particularly for more problematic cases.Keywords
This publication has 20 references indexed in Scilit:
- The Effects of Olanzapine on the 5 Dimensions of Schizophrenia Derived by Factor AnalysisBritish Journal of Psychology, 2001
- Double-blind olanzapine vs. haloperidol D2 dopamine receptor blockade in schizophrenic patients: a baseline-endpoint [123I]IBZM SPECT studyPsychiatry Research: Neuroimaging, 2001
- Focus on OlanzapineCurrent Medical Research and Opinion, 1999
- Novel antipsychotics and the problem of clinical stabilization in schizophreniaInternational Clinical Psychopharmacology, 1996
- Olanzapine versus Placebo and HaloperidolNeuropsychopharmacology, 1996
- Electrophysiological Effects of Olanzapine, a Novel Atypical Antipsychotic, on A9 and A10 Dopamine NeuronsNeuropsychopharmacology, 1996
- Depression, demoralization and control over psychotic illness: a comparison of depressed and non-depressed patients with a chronic psychosisPsychological Medicine, 1993
- Depression in Chronic SchizophreniaThe British Journal of Psychiatry, 1983
- A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTSActa Psychiatrica Scandinavica, 1970
- A RATING SCALE FOR DEPRESSIONJournal of Neurology, Neurosurgery & Psychiatry, 1960